U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 3Cl.Ga
Molecular Weight 173.287
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GALLIUM CHLORIDE GA-67

SMILES

[Cl-].[Cl-].[Cl-].[67Ga+3]

InChI

InChIKey=UPWPDUACHOATKO-MPZFSRPWSA-K
InChI=1S/3ClH.Ga/h3*1H;/q;;;+3/p-3/i;;;1-3

HIDE SMILES / InChI

Molecular Formula Ga
Molecular Weight 66.9282
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation, allowing scintigraphic localization. Ga-67 scintigraphy (GS) cannot differentiate between tumor and acute inflammation. Gallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
GALLIUM CITRATE GA 67

Approved Use

Gallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state.

Launch Date

1976
Primary
GALLIUM CITRATE GA 67

Approved Use

Gallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state.

Launch Date

1976
Primary
GALLIUM CITRATE GA 67

Approved Use

Gallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state.

Launch Date

1976

Sample Use Guides

DOSAGE AND ADMINISTRATION: The recommended adult (70 kg) dose of Gallium Citrate Ga 67 Injection is 74-185 MBq (2-5 mCi). Gallium Citrate Ga 67 Injection is intended for intravenous administration only
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 15 18:35:36 GMT 2023
Edited
by admin
on Fri Dec 15 18:35:36 GMT 2023
Record UNII
A04B19O2B0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GALLIUM CHLORIDE GA-67
Common Name English
GALLIUM (GA-67) CHLORIDE
Common Name English
GALLIUM CHLORIDE GA 67
Common Name English
GALLIUM CHLORIDE,GA-67
VANDF  
Common Name English
GALLIUM CHLORIDE, GA-67
Common Name English
GALLIUM (67GA) CHLORIDE
Common Name English
GALLIUM CHLORIDE,GA-67 [VANDF]
Common Name English
Code System Code Type Description
DRUG BANK
DB14550
Created by admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
PRIMARY
DAILYMED
A04B19O2B0
Created by admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
PRIMARY
RXCUI
314639
Created by admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
PRIMARY RxNorm
PUBCHEM
73415785
Created by admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
PRIMARY
FDA UNII
A04B19O2B0
Created by admin on Fri Dec 15 18:35:36 GMT 2023 , Edited by admin on Fri Dec 15 18:35:36 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY